Skip to Content

Generic Zerviate Availability

Zerviate is a brand name of cetirizine ophthalmic, approved by the FDA in the following formulation(s):

ZERVIATE (cetirizine hydrochloride - solution/drops;ophthalmic)

  • Manufacturer: EYEVANCE PHARMS
    Approval date: May 30, 2017
    Strength(s): EQ 0.24% BASE [RLD]

Has a generic version of Zerviate been approved?

No. There is currently no therapeutically equivalent version of Zerviate available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zerviate. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Ophthalmic formulations of cetirizine and methods of use
    Patent 8,829,005
    Issued: September 9, 2014
    Assignee(s): Aciex Therapeutics, Inc.
    The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
    Patent expiration dates:
    • March 15, 2030
      ✓ 
      Patent use: TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
    • September 15, 2030
      ✓ 
      Pediatric exclusivity
  • Ophthalmic formulations of cetirizine and methods of use
    Patent 9,254,286
    Issued: February 9, 2016
    Assignee(s): Aciex Therapeutics, Inc.
    The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
    Patent expiration dates:
    • July 9, 2032
      ✓ 
      Drug product
    • January 9, 2033
      ✓ 
      Pediatric exclusivity
  • Ophthalmic formulations of cetirizine and methods of use
    Patent 9,750,684
    Issued: September 5, 2017
    Assignee(s): Nicox Ophthalmics, Inc.
    The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
    Patent expiration dates:
    • March 15, 2030
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 30, 2020 - NEW DOSAGE FORM
    • November 30, 2020 - PEDIATRIC EXCLUSIVITY

More about Zerviate (cetirizine ophthalmic)

Consumer resources

Related treatment guides

Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide